Category: 3. Business

  • Using generative AI to diversify virtual training grounds for robots | MIT News

    Using generative AI to diversify virtual training grounds for robots | MIT News

    Chatbots like ChatGPT and Claude have experienced a meteoric rise in usage over the past three years because they can help you with a wide range of tasks. Whether you’re writing Shakespearean sonnets, debugging code, or need an answer to an obscure trivia question, artificial intelligence systems seem to have you covered. The source of this versatility? Billions, or even trillions, of textual data points across the internet.

    Those data aren’t enough to teach a robot to be a helpful household or factory assistant, though. To understand how to handle, stack, and place various arrangements of objects across diverse environments, robots need demonstrations. You can think of robot training data as a collection of how-to videos that walk the systems through each motion of a task. Collecting these demonstrations on real robots is time-consuming and not perfectly repeatable, so engineers have created training data by generating simulations with AI (which don’t often reflect real-world physics), or tediously handcrafting each digital environment from scratch.

    Researchers at MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) and the Toyota Research Institute may have found a way to create the diverse, realistic training grounds robots need. Their “steerable scene generation” approach creates digital scenes of things like kitchens, living rooms, and restaurants that engineers can use to simulate lots of real-world interactions and scenarios. Trained on over 44 million 3D rooms filled with models of objects such as tables and plates, the tool places existing assets in new scenes, then refines each one into a physically accurate, lifelike environment.

    Steerable scene generation creates these 3D worlds by “steering” a diffusion model — an AI system that generates a visual from random noise — toward a scene you’d find in everyday life. The researchers used this generative system to “in-paint” an environment, filling in particular elements throughout the scene. You can imagine a blank canvas suddenly turning into a kitchen scattered with 3D objects, which are gradually rearranged into a scene that imitates real-world physics. For example, the system ensures that a fork doesn’t pass through a bowl on a table — a common glitch in 3D graphics known as “clipping,” where models overlap or intersect.

    How exactly steerable scene generation guides its creation toward realism, however, depends on the strategy you choose. Its main strategy is “Monte Carlo tree search” (MCTS), where the model creates a series of alternative scenes, filling them out in different ways toward a particular objective (like making a scene more physically realistic, or including as many edible items as possible). It’s used by the AI program AlphaGo to beat human opponents in Go (a game similar to chess), as the system considers potential sequences of moves before choosing the most advantageous one.

    “We are the first to apply MCTS to scene generation by framing the scene generation task as a sequential decision-making process,” says MIT Department of Electrical Engineering and Computer Science (EECS) PhD student Nicholas Pfaff, who is a CSAIL researcher and a lead author on a paper presenting the work. “We keep building on top of partial scenes to produce better or more desired scenes over time. As a result, MCTS creates scenes that are more complex than what the diffusion model was trained on.”

    In one particularly telling experiment, MCTS added the maximum number of objects to a simple restaurant scene. It featured as many as 34 items on a table, including massive stacks of dim sum dishes, after training on scenes with only 17 objects on average.

    Steerable scene generation also allows you to generate diverse training scenarios via reinforcement learning — essentially, teaching a diffusion model to fulfill an objective by trial-and-error. After you train on the initial data, your system undergoes a second training stage, where you outline a reward (basically, a desired outcome with a score indicating how close you are to that goal). The model automatically learns to create scenes with higher scores, often producing scenarios that are quite different from those it was trained on.

    Users can also prompt the system directly by typing in specific visual descriptions (like “a kitchen with four apples and a bowl on the table”). Then, steerable scene generation can bring your requests to life with precision. For example, the tool accurately followed users’ prompts at rates of 98 percent when building scenes of pantry shelves, and 86 percent for messy breakfast tables. Both marks are at least a 10 percent improvement over comparable methods like “MiDiffusion” and “DiffuScene.”

    The system can also complete specific scenes via prompting or light directions (like “come up with a different scene arrangement using the same objects”). You could ask it to place apples on several plates on a kitchen table, for instance, or put board games and books on a shelf. It’s essentially “filling in the blank” by slotting items in empty spaces, but preserving the rest of a scene.

    According to the researchers, the strength of their project lies in its ability to create many scenes that roboticists can actually use. “A key insight from our findings is that it’s OK for the scenes we pre-trained on to not exactly resemble the scenes that we actually want,” says Pfaff. “Using our steering methods, we can move beyond that broad distribution and sample from a ‘better’ one. In other words, generating the diverse, realistic, and task-aligned scenes that we actually want to train our robots in.”

    Such vast scenes became the testing grounds where they could record a virtual robot interacting with different items. The machine carefully placed forks and knives into a cutlery holder, for instance, and rearranged bread onto plates in various 3D settings. Each simulation appeared fluid and realistic, resembling the real-world, adaptable robots steerable scene generation could help train, one day.

    While the system could be an encouraging path forward in generating lots of diverse training data for robots, the researchers say their work is more of a proof of concept. In the future, they’d like to use generative AI to create entirely new objects and scenes, instead of using a fixed library of assets. They also plan to incorporate articulated objects that the robot could open or twist (like cabinets or jars filled with food) to make the scenes even more interactive.

    To make their virtual environments even more realistic, Pfaff and his colleagues may incorporate real-world objects by using a library of objects and scenes pulled from images on the internet and using their previous work on “Scalable Real2Sim.” By expanding how diverse and lifelike AI-constructed robot testing grounds can be, the team hopes to build a community of users that’ll create lots of data, which could then be used as a massive dataset to teach dexterous robots different skills.

    “Today, creating realistic scenes for simulation can be quite a challenging endeavor; procedural generation can readily produce a large number of scenes, but they likely won’t be representative of the environments the robot would encounter in the real world. Manually creating bespoke scenes is both time-consuming and expensive,” says Jeremy Binagia, an applied scientist at Amazon Robotics who wasn’t involved in the paper. “Steerable scene generation offers a better approach: train a generative model on a large collection of pre-existing scenes and adapt it (using a strategy such as reinforcement learning) to specific downstream applications. Compared to previous works that leverage an off-the-shelf vision-language model or focus just on arranging objects in a 2D grid, this approach guarantees physical feasibility and considers full 3D translation and rotation, enabling the generation of much more interesting scenes.”

    “Steerable scene generation with post training and inference-time search provides a novel and efficient framework for automating scene generation at scale,” says Toyota Research Institute roboticist Rick Cory SM ’08, PhD ’10, who also wasn’t involved in the paper. “Moreover, it can generate ‘never-before-seen’ scenes that are deemed important for downstream tasks. In the future, combining this framework with vast internet data could unlock an important milestone towards efficient training of robots for deployment in the real world.”

    Pfaff wrote the paper with senior author Russ Tedrake, the Toyota Professor of Electrical Engineering and Computer Science, Aeronautics and Astronautics, and Mechanical Engineering at MIT; a senior vice president of large behavior models at the Toyota Research Institute; and CSAIL principal investigator. Other authors were Toyota Research Institute robotics researcher Hongkai Dai SM ’12, PhD ’16; team lead and Senior Research Scientist Sergey Zakharov; and Carnegie Mellon University PhD student Shun Iwase. Their work was supported, in part, by Amazon and the Toyota Research Institute. The researchers presented their work at the Conference on Robot Learning (CoRL) in September.

    Continue Reading

  • Salesforce to spend $1 billion in Mexico over next five years to drive AI adoption

    Salesforce to spend $1 billion in Mexico over next five years to drive AI adoption

    Oct 8 (Reuters) – Salesforce (CRM.N), opens new tab said on Wednesday it would spend $1 billion in Mexico over the next five years, as the cloud software provider looks to expand its operations and drive artificial intelligence adoption.

    The company, which began operating in Mexico in 2006, said the investment will fund a new Mexico City office and a Global Delivery Center to support customers across the Americas.

    Sign up here.

    “This $1 billion investment is a commitment to Mexico as a key market for AI-powered growth,” CEO Marc Benioff said.

    Mexico is rapidly emerging as a tech services hub, drawing investments from technology companies, particularly in the AI domain due to the country’s proximity to the U.S. and growing talent base.

    Microsoft (MSFT.O), opens new tab announced last year that it will spend $1.3 billion over the next three years to build up its infrastructure in Mexico for cloud computing and AI.

    Salesforce said Mexico is a growth market for the company, with a customer base including organizations such as Xcaret, Grupo Bafar and FEMSA.

    “This investment will not only create jobs and build AI skills within Mexico but will also position our country as a key consultancy hub for markets across Latin America on AI agents and more,” Mexico’s Economy Minister Marcelo Ebrard said.

    Last month, Salesforce forecast third-quarter revenue below Wall Street estimates. The company had also announced a $20 billion increase to its existing share buyback program.

    Salesforce has rolled out AI across its cloud services at a rapid pace, culminating in the 2024 commercial launch of Agentforce — its AI agent platform designed to automate tasks, streamline operations and help lift margins.

    Reporting by Jaspreet Singh in Bengaluru; Editing by Alan Barona

    Our Standards: The Thomson Reuters Trust Principles., opens new tab

    Continue Reading

  • Access Denied


    Access Denied

    You don’t have permission to access “http://www.spglobal.com/market-intelligence/en/news-insights/articles/2025/10/four-10b-m-a-deals-in-september-push-q3-to-2025-high-93605742” on this server.

    Reference #18.2d91102.1759943422.5699a1b3

    https://errors.edgesuite.net/18.2d91102.1759943422.5699a1b3

    Continue Reading

  • Preparing Your Organisation for CSRD Through Strategic Scenario Planning

    Preparing Your Organisation for CSRD Through Strategic Scenario Planning

    Organisations across Europe are navigating a pivotal moment. The accelerating pace of change, driven by political shifts, economic uncertainty, social transformation, rapid technological advances, and intensifying environmental pressures (PESTLE), is demanding bold and resilient leadership. The EU’s Corporate Sustainability Reporting Directive (CSRD),1 alongside sister directives such as the EU’s Pay Transparency Directive2 and the Corporate Sustainability Due Diligence Directive (CSDDD),3 adds to this urgency by setting new benchmarks for how companies account for their social and environmental impacts.

    The CSRD calls for greater transparency around how businesses are measuring and addressing material sustainability risks and impacts, including those related to diversity, equity, inclusion (DEI), and human rights across the value chain. Complying with CSRD requires more than meeting reporting obligations; it demands a deeper understanding of how sustainability and inclusion intersect with business performance and long-term risk.4 But many organisations struggle to build this understanding and embed CSRD’s principles into strategies and practices.

    At the same time, European organisations are keeping a close eye on developments across the Atlantic, where evolving regulatory frameworks — whether directly applicable or indirectly influential — are creating ripple effects that further complicate the compliance landscape. For global organisations, this transatlantic dynamic adds another layer of complexity, reinforcing the need for strategic clarity and adaptive leadership.

    If you are a leader responsible for CSRD, this tool provides a structured way for you to bring together key stakeholders — across HR, DEI, legal, finance, and sustainability — to align priorities and co-develop strategic responses. It supports organisational efforts to address compliance requirements and go further, enabling scenario-based planning that is inclusive, forward-looking, and grounded in cross-functional collaboration.

    This tool will enable you to:

    • Navigate the “S” in ESG through structured scenario planning that aligns with CSRD requirements.
    • Identify and prioritise material social risks and opportunities across the value chain.
    • Stress-test organisational readiness through three future-facing scenarios:
      • Mandatory CSRD disclosures expose existing diversity, equity, and inclusion gaps.
      • AI bias in ESG tools skews CSRD disclosures.
      • Divergence in regulations and budgetary commitment to inclusion across markets complicates CSRD compliance.

    How to cite: Smith, E. & Penda, V. (2025). Preparing your organisation for CSRD through strategic scenario planning. Catalyst.

    Continue Reading

  • FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma

    FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma

    The FDA has granted fast track designation to VT3989, a transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, for the treatment of patients with unresectable malignant nonpleural or pleural mesothelioma who have progressed on prior immune checkpoint inhibition and platinum-based chemotherapy.1

    “We are pleased to receive fast track designation from the FDA for VT3989 in this patient population, which is in desperate need of new and effective therapeutic options,” Sofie Qiao, PhD, president and chief executive officer of Vivace Therapeutics, the developer of VT3989, stated in a news release. “This designation represents another important step in our ongoing development of VT3989 and will offer key advantages as we continue on our path toward potential commercialization of this first-in-class and best-in-class therapy.”

    VT3989 Pipeline Update

    • The FDA granted fast track designation to VT3989, a transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, for the treatment of patients with unresectable malignant nonpleural or pleural mesothelioma who have progressed on prior immune checkpoint inhibition and platinum-based chemotherapy.
    • VT3989 is a novel, investigational small molecule designed to inhibit palmitoylation of members of the TEAD protein family, thereby targeting the Hippo pathway.
    • Preliminary efficacy findings presented from the dose-escalation portion of the ongoing phase 1/2 trial showed decreases in the sum of the target lesions from baseline among patients with both pleural and non-pleural mesothelioma, regardless of their NF2 mutation status.

    What Is the Mechanism of Action of VT3989?

    This novel, investigational small molecule therapeutic is designed to inhibit palmitoylation of members of the TEAD protein family, thus targeting the Hippo pathway. The efficacy and safety of VT3989 are under investigation in an ongoing phase 1/2 clinical trial (NCT04665206).

    What Is the Design of the Phase 1/2 Trial?

    This multicenter, open-label trial is enrolling patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.2 Patients need to have an ECOG performance status of 0 or 1, as well as adequate organ function.

    This trial consists of 3 parts. The dose-escalation part investigated the safety of VT3989 in patients with mesothelioma or metastatic solid tumors. Patients received the agent in a 3+3 design until the maximum tolerated dose or recommended phase 2 schedule and dose are identified.

    The dose-expansion part assessed the safety and preliminary antitumor activity of VT3989 at the recommended phase 2 schedule and dose in up to 6 cohorts, including patients with mesothelioma of any site origin regardless of NF2 mutation status (cohorts 1 and 2), patients with non-pleural mesothelioma (cohort 3), patients with solid tumors with clearly inactivating NF2 alterations or mutations or YAP/TAZ gene rearrangements (cohort 4), and patients with pleural mesothelioma (cohort 5).

    The combination part will consist of 2 cohorts. Cohort A will enroll patients with mesothelioma who will be treated with VT3989 plus nivolumab (Opdivo) or ipilimumab (Yervoy). Cohort B will enroll patients with non–small cell lung cancer with tumors harboring EGFR exon 19 deletions or EGFR exon 21 L858R mutations who will be treated with VT3989 plus osimertinib.

    VT3989 is administered orally in 25-mg, 50-mg, 100-mg, 150-mg, or 200-mg capsules over 21- or 28-day cycles.

    The primary end point is the occurrence of dose-limiting toxicities and the occurrence of general toxicities. Secondary end points include tumor response; pharmacokinetic evaluations; overall survival in part 2 cohorts 3, 4, and 5; progression-free survival in part 2 cohorts 3, 4, and 5; and quality of life in part 2 cohorts 3, 4, and 5.

    What Is the Efficacy of VT3989 in Patients With Mesothelioma?

    Findings from the dose-escalation portion of the trial, presented at the 2023 IASLC World Conference on Lung Cancer, showed decreases in the sum of the target lesions from baseline among patients with both pleural and non-pleural mesothelioma who received the agent across dose levels and schedules.3 Responses were observed regardless of NF2 mutation status.

    What Is the Safety Profile of VT3989 in Patients With Mesothelioma?

    Among evaluable patients with mesothelioma (n = 44), the most common grade 1 to 4 treatment-related adverse effects included albuminuria (61.6%), proteinuria (59.1%), fatigue (31.8%), peripheral edema (29.5%), nausea (20.5%), increased alanine aminotransferase levels (13.6%), increased aspartate aminotransferase levels (13.6%), anemia (11.4%), and decreased appetite (11.4%).

    References

    1. Vivace Therapeutics’ VT3989 granted fast track designation by the U.S. Food and Drug Administration for the treatment of mesothelioma. News release. Vivace Therapeutics, Inc. October 8, 2025. Accessed October 8, 2025. https://www.prnewswire.com/news-releases/vivace-therapeutics-vt3989-granted-fast-track-designation-by-the-us-food-and-drug-administration-for-the-treatment-of-mesothelioma-302577269.html
    2. Study to evaluate VT3989 in patients with metastatic solid tumors.ClinicalTrials.gov. Updated August 11, 2025. Accessed October 8, 2025. https://clinicaltrials.gov/study/NCT04665206
    3. Yap T, Desai J, Dagogo-Jack I, et al. First-in-human phase 1 trial of VT3989, a first-in-class YAP/TEAD inhibitor in patients with advanced mesothelioma. Presented at: 2023 IASLC World Conference on Lung Cancer. September 9-12, 2023; Singapore.

    Continue Reading

  • ADVISORY: Embargoed Press Call on the State of Climate Action 2025 Report

    WASHINGTON (October 8, 2025) – Join an embargoed press call to preview the State of Climate Action 2025 report on Thursday, October 16, 2025, from 9:00–10:00 a.m. ET / 3:00–4:00 p.m. CEST, hosted by Systems Change Lab partners — the Bezos Earth Fund, Climate Analytics and World Resources Institute.  

    Released in the lead-up to COP30 and ahead of the Paris Agreement’s tenth anniversary, the State of Climate Action 2025 offers the world’s most comprehensive roadmap for how every major sector must close the climate action gap and help limit warming to 1.5°C.  

    The report translates this Paris Agreement temperature goal into clear, sector-by-sector targets for 2030, 2035, and 2050 — across power, buildings, industry, transport, forests and land, and food and agriculture — and assesses whether the world is on pace to meet them. It also evaluates progress made in scaling technological carbon dioxide removal (CDR) and climate finance, both of which are essential for achieving global climate goals.  

    During the call, report authors will share key findings, sector insights and discuss the report’s relevance to global climate efforts, including updated national climate commitments (NDCs), the Global Stocktake and COP30. Following the presentations, we’ll open the floor to questions from the media. 

    REGISTER HERE  

    The findings in theState of Climate Action 2025report are strictly embargoed until Wednesday, October 22, 2025, at 00:01 ET / 06:01 CEST.Embargoed materials will be available upon request starting Monday, October 13. Please contact Darla van Hoorn at [email protected]  to request access. 
     
    WHEN  

    Thursday, October 16, 2025, from 9:00–10:00 a.m. ET / 3:00–4:00 p.m. CEST 

    WHO    
    Speakers 

    • Kelly Levin, Chief of Science, Data and Systems Change, the Bezos Earth Fund; Co-Director of Systems Change Lab
    • Clea Schumer, Research Associate, Systems Change Lab, World Resources Institute 
    • Sophie Boehm, Senior Research Associate, Systems Change Lab, World Resources Institute
    • Alison Cinnamond (moderator), Strategic Communications and Media Director, World Resources Institute 

    Expert respondents 

    • Neil Grant, Senior Climate and Energy Analyst, Climate Analytics
    • Joel Jaeger, Senior Research Associate, Systems Change Lab, World Resources Institute
    • Anderson Lee, Research Associate II, World Resources Institute  

    RSVP   
    Please RSVP at the following Zoom link. This call is open to journalists only.  
     

    Continue Reading

  • Celebrating milestones and the future of oncology in China

    Celebrating milestones and the future of oncology in China

    China’s biopharmaceutical innovation is experiencing an unprecedented period of growth. Thanks to sustained policy support, capital investment, and expanding research capabilities, the country is rapidly increasing its reputation as a global hub of innovation. According to the WHO, in 2024 China ranked second in the world for number of registered clinical trials, and over the past decade, its new pharmaceutical and medical technology patents have nearly quadrupled.

    Against this backdrop, the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held this month in Jinan, Shandong Province. As one of the most influential academic platforms in the field, CSCO has become a key venue for showcasing China’s oncology research to the world, and this year’s meeting shined a spotlight on the latest advances in cancer prevention, diagnosis, and treatment across both research and clinical practice.

    Partnering with leading experts in oncology, molecular pathology, and drug development, Illumina hosted a special session at the conference that facilitated in-depth exchanges on biomarker applications in solid tumors, cancer drug innovation, and precision medicine in the Guangdong–Hong Kong–Macao Greater Bay Area.

    Advances in next-generation sequencing and multiomics

    Cancer therapy is undergoing a profound transformation, as subtypes are increasingly defined on a molecular basis rather than on organs or histology. With advances in next-generation sequencing (NGS), researchers can now integrate genomic, transcriptomic, proteomic, and other layers of biological information to achieve a comprehensive view of tumors. Large-scale genomics and multiomics projects are also enriching our understanding of cancer initiation and progression, opening new possibilities for precise tumor classification and translational research.

    Professor Zhang Xuchao of Guangdong Provincial People’s Hospital noted that “NGS and multiomics, as core tools in the life sciences, are enabling us to more precisely identify disease drivers and transition from single-target to multi-biomarker-driven approaches. By analyzing diseases at the molecular level, we can trace their evolutionary pathways, identify potential therapeutic targets, and accelerate the translation of scientific discoveries into clinical applications.”

    From the frontiers of research to clinical practice

    As clinical practice increasingly adopts NGS, improving the accessibility and efficiency of precision oncology remains a top priority for clinicians. Comprehensive genomic profiling (CGP) is a core tool for detecting cancer biomarkers and enabling a thorough analysis of genomic alterations in tumors. It helps identify variants linked to disease progression and drug sensitivity, significantly improving the accuracy of targeted therapy matching.

    “China urgently needs breast cancer clinical research that is more tailored to local populations,” said Professor Cao Wenming of Zhejiang Cancer Hospital. “Systematic and highly sensitive genomics testing can guide clinical practice, significantly improve patient outcomes, and open up new therapeutic pathways.”

    Professor Song Wei, director of Clinical Genomics and Molecular Pathology at UC San Diego Health, shared, “I’m deeply focused on advancing in-house genomics testing to help pathologists in classifying tumors more rapidly. CGP assays provide streamlined end-to-end workflow and integrated analytics, delivering rapid, high-quality results that meet the dual demands of speed and accuracy for in-house testing. By building local projects and databases, we are also advancing real-world research, using data to enhance both accessibility and clinical value of precision medicine.”

    As NGS and multiomics technologies generate large-scale datasets, Illumina is empowering deeper analyses through bioinformatics software and AI. Recently, the UK Biobank identified 1.5 billion variants from nearly 500,000 whole genomes with Illumina software. The dataset was published in Nature and is now openly accessible to pharmaceutical partners worldwide.

    Synergy between research and medicine

    In China, multiomics, AI, and other advanced tools are increasingly embedded across the cancer care continuum. During a live discussion at the CSCO meeting, Professor Gao Chenyan, leading scientist at Changping Laboratory, emphasized that clinical research is a key driver of innovative drug development and the optimization of treatment pathways. Professor Ma Jun, director of the Harbin Institute of Hematology and Oncology (HIHO), elaborated: “Hematologic tumors are highly heterogeneous. Cutting-edge technologies such as NGS have greatly enhanced our ability to monitor tumor heterogeneity. NGS-based ctDNA assays offer high specificity and sensitivity, making them reliable tools for detecting minimal residual disease in B-cell lymphoma and for assessing treatment response. Driving innovation in cancer diagnosis and treatment requires close collaboration across research, clinical practice, and industry—all for the benefit of patients.”

    A “pilot-first” model for innovation

    The Guangdong–Hong Kong–Macao Greater Bay Area (GBA) has become an important bridge for introducing innovative diagnostic and therapeutic solutions into mainland China, thanks to a Hong Kong Department of Health measure announced in November 2020. By June 2025, the measure had covered 45 designated hospitals, introduced 51 drugs and 63 devices, and benefited tens of thousands of patients in the GBA.

    Kang Wei, former managing director of the R&D-Based Pharmaceutical Association Committee, noted that “China has become an important source of drug innovation, with growing impact in international clinical trials. GBA’s biopharmaceutical industry is uniquely positioned to leverage the measure, offering an open window for applying innovative medical resources. This has attracted leading global partners to explore practical solutions and accelerate the translation of new drugs and devices from bench to bedside.”

    Illumina continues to invest in research and clinical solutions to expand advanced tumor profiling and meet diverse biomarker testing needs. In August 2024, the FDA approved TruSight Oncology Comprehensive, the first United States FDA–approved distributable comprehensive genomic profiling in vitro diagnostic with pan-cancer companion diagnostic claims.

    Au Siu Kie, a professor at the Hong Kong Integrated Oncology Centre and coauthor of the JCO Precision Oncology paper “Consensus Statements on Precision Oncology in the China Greater Bay Area,” also spoke about how the measure, and expert consensus, are transforming cancer care: “This year, FDA-approved products such as TSO Comprehensive are expected to become available in Hong Kong, expanding access to advanced CGP options for patients.” He added that this broadens the reach of precision medicine and helps improve the affordability of internationally approved therapies under local reimbursement systems, “which ultimately benefits more patients.”

    Deepening local innovation

    Illumina continues to expand local investment and strengthen customer service and support in China. As of this June, the registration of certain Illumina products by its commercial partner Berry Genomics enabled high-throughput clinical sequencing for applications in genetic disease, reproductive health, and oncology. This year, Illumina also launched its Beijing Customer Engagement Center and its official e-commerce platform on WeChat, creating a full-channel service ecosystem.

    Jenny Zheng, global senior vice president and the company’s general manager of Greater China, said: “We will work hand in hand with experts at home and abroad to accelerate translation of scientific discoveries, ensuring that cutting-edge technologies truly benefit patients. As oncology research in China continues to deepen and innovative technologies gain wider adoption, the synergistic development of NGS and multiomics, combined with our localization strategy, will contribute China’s wisdom and solutions to global cancer prevention and treatment.”

    Continue Reading

  • Kirkland Represents CF PharmTech on its Hong Kong Listing | News

    Kirkland & Ellis advised CF PharmTech, Inc. (CF PharmTech, HKEx: 2652) on its global offering and listing on the Main Board of the Hong Kong Stock Exchange. The joint sponsors for the listing were CITIC Securities (Hong Kong) Limited and CMB International Capital Limited.

    CF PharmTech raised approximately HK$607.7 million from its global offering, which has attracted strong interest and overwhelming demand from the capital markets. The Hong Kong public offering tranche was oversubscribed by approximately 6,700 times, ranking among the top three most oversubscribed IPOs on the HKEx in 2025. The international offering tranche was also oversubscribed by approximately 12.74 times, drawing participation from numerous well-known institutional investors and high-quality long-term capital. The enthusiastic response reflects strong market confidence in CF PharmTech’s growth potential and business prospects.

    CF PharmTech primarily focuses on the R&D, manufacturing and commercialization of inhalation technologies and inhalation drugs, with a focus on treating respiratory diseases. It has developed a product portfolio with a broad coverage of patients, medical specialties and therapeutic areas. CF PharmTech intends to apply the proceeds to fund the ongoing R&D and clinical development of its established inhalation formulation product candidates, both domestically and internationally, its pre-clinical R&D across multiple other pipeline programs and technologies, expansion and upgrade of its manufacturing facilities, equipment procurement, and production management systems and working capital and other general corporate purposes.

    Kirkland & Ellis’s Asia capital markets team continues to deepen its focus on the life sciences sector, and the CF PharmTech’s IPO represents another milestone transaction in this space.

    The Kirkland team included capital markets lawyers Mengyu Lu, Samantha Peng, George Zheng, and Yuchen Han; registered foreign lawyers Bill Feng, Jiawei Zhao, Ashley Sun and Qianqian Yu.

    Continue Reading

  • Oil prices edge up on worries about Russian output and limited OPEC+ production increase – Reuters

    1. Oil prices edge up on worries about Russian output and limited OPEC+ production increase  Reuters
    2. Oil rises as oversupply fear eases after OPEC+ restrains output increase  Reuters
    3. OPEC Nears Its Limit, Leaving Prices One Crisis Away from a Spike  Crude Oil Prices Today | OilPrice.com
    4. Crude Prices Slip on Dollar Strength and Energy Demand Concerns  TradingView
    5. OPEC+ lifts production, petrol price likely to go down  MobilityEnergy.com

    Continue Reading

  • Amazon announces plans to invest over €1 billion to enhance Belgian customer experience

    Amazon announces plans to invest over €1 billion to enhance Belgian customer experience

    During a Belgian Economic Mission to the West Coast of the USA, today we announced plans to invest over €1 billion in Belgium from 2025-2027. This investment continues Amazon’s commitment to innovation and providing an even better experience to customers through low prices, selection, and convenience, while helping small businesses in Belgium succeed.

    This represents our largest investment in Belgium to date, supporting jobs, infrastructure development, and Belgian partnerships including our continued work with bpost, Belgium’s national postal operator. In addition to supporting our Belgian customers, these investments will also help small and medium-sized businesses to expand their reach to customers both in Belgium and internationally, helping them grow their businesses while supporting job creation and economic growth. The announcement builds upon our growing presence in Belgium since opening our first office in 2015 and launching amazon.com.be in 2022. After investing more than €250 million in 2023 and €300 million in 2024, this new announcement accelerates our planned investment in the Belgian economy.

    Eva Faict, Country Manager for Amazon Belgium and the Netherlands

    “Our planned investment of more than a billion euros in Belgium will go towards expanding our logistics network, enhancing our delivery capabilities, and strengthening our local infrastructure to better serve Belgian customers,” said Eva Faict, Country Manager for Amazon Belgium and the Netherlands. “Since launching amazon.com.be in October 2022, we’ve helped more than a thousand Belgian businesses reach new customers, created hundreds of local jobs, and worked with local delivery partners. This new investment will allow us to further support Belgian entrepreneurs with our technology and expertise, while continuing to offer customers low prices, wider product selection, and faster delivery options.”

    Economic impact and growth

    We have invested more than €800 million in Belgium since 2015. We now employ over 400 people across Belgium, from our Belgian headquarters in Brussels including AWS, to our delivery station in Antwerp, and our Mechatronics Research & Development Center in Hamme. In 2024 alone, third-party research by Keystone Strategy[1] estimates that our investments supported more than 1,000 indirect jobs and 200 induced jobs[2] in construction, logistics, and professional services.

    “Amazon’s investment is a powerful endorsement of our region’s economic strengths. As a government, we are committed to fostering innovation and supporting companies that create sustainable jobs and economic opportunities across our regions. This significant investment demonstrates that our region continues to attract global technology leaders, strengthening our position as a strategic hub for digital commerce in Europe,” said Matthias Diependaele, Minister-President of Flanders.

    According to Keystone estimates, Amazon’s investments contributed more than €140 million to Belgium’s GDP in 2024, with more than €350 million to Belgium GDP since 2015.

    Supporting Belgian Small and Medium-sized Enterprises

    The 2024 Amazon SME Impact Report[3] shows that Belgian SMEs have achieved remarkable international success through e-commerce, with 90% of businesses selling on Amazon exporting their products internationally. These SMEs generated over €350 million in total export sales in 2023, demonstrating the store’s effectiveness in helping Belgian businesses expand internationally.

    “Amazon’s €1 billion investment solidifies Belgium’s role as a leading hub for innovation and digital transformation, driving competitiveness, fostering job creation, and fueling economic growth. Today’s announcement demonstrates the strong potential of e-commerce for businesses of all sizes, with particular promise for Belgian SMEs. We see how this lever can help local entrepreneurs strengthen their market presence and even expand beyond borders, reaching millions of customers across Europe and beyond” said Eléonore Simonet, Belgian Minister for SMEs, Self-Employed and Small Businesses.

    Building a more sustainable future

    As a co-founder of The Climate Pledge, with the goal of reaching net-zero carbon by 2040 – an ambitious commitment we are actively working towards – Amazon is investing in sustainability across its businesses to drive down carbon emissions. Amazon’s commitment to sustainability takes root in concrete actions, from investing in the National Park Brabantse Wouden’s scientific research and habitat restoration to funding technology solutions that enhance biodiversity monitoring and visitor experience in Belgium’s newest national park with Leuven MindGate. We are decarbonising last-mile deliveries across Belgium, with over 9 out of 10 parcels delivered to customers by electric vans in Antwerp and electric cargo bikes serving Brussels’ Pentagon area. More than 50% of European shipments now come in reduced delivery packaging, such as a paper bag or cardboard envelope, or with no added packaging at all. To help customers in Belgium to make environmentally conscious choices, Amazon has launched the Climate Pledge Friendly programme, which features products that are certified by one or more of over 50 sustainability certifications, and to help customers give products a second life, they can take advantage of Amazon Used, Trade-in programs, and the Fix-it store. These initiatives demonstrate Amazon’s holistic approach to environmental stewardship, combining technological innovation, operational excellence, and customer empowerment to build a more sustainable future.

    [1] All investment and economic impact figures have been estimated by Keystone Strategy, an independent macroeconomic consultancy.
    [2] Indirect jobs = jobs supported through business-to-business transactions (supply chain)
    Induced jobs = jobs supported through consumer spending of direct and indirect employees
    [3] 2024 Amazon Small and Medium-sized Impact Report available here.


    Continue Reading